New T cell therapy targets CTNNB1 cancer mutation with promising results in animal studies

Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers like lung and prostate cancer.